Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Clinical-stage biotech develops cell and gene therapies using CRISPR-enabled gene editing for solid tumors and genetic diseases.
CureGenetics is a clinical-stage biotechnology company based in Suzhou, China, that develops cell and gene therapies for solid tumors and common genetic diseases using targeted gene editing platforms. The organization utilizes its AIMS CAR-NKT and VELP AAV technologies to create CRISPR-enabled treatments and molecular diagnostics for complex oncology indications and familial neurological disorders, including Alzheimer's, Parkinson's, and Huntington's disease. In 2018, the enterprise raised $17 million in an initial Series A funding round led by Qiming Venture Partners, alongside participation from CTS Capital and Ascendin Investment. The firm advances its clinical pipeline through global out-licensing agreements, highlighted by a 2023 collaboration with Frametact Limited that secured $60 million in upfront and milestone payments. CureGenetics was founded in 2016 by Yuanyuan Xu, who leads the business alongside former Voyager Therapeutics founding scientist Pengcheng Zhou.
CureGenetics has raised $96.0M across 4 funding rounds.
CureGenetics has raised $96.0M in total across 4 funding rounds.
CureGenetics has raised $96.0M in total across 4 funding rounds.
CureGenetics's investors include Formic Ventures, Qiming Venture Partners, Bill Gates, Scott Becker, Ascendin Investment, CTS Capital.
CureGenetics has raised $96.0M across 4 funding rounds. Most recently, it raised $9.0M Series B in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2024 | $9M Series B | — | Formic Ventures, Qiming Venture Partners, Bill Gates, Scott Becker | Announced |
| Jan 1, 2022 | $60M Series B | — | Formic Ventures, Qiming Venture Partners, Bill Gates, Scott Becker | Announced |
| Mar 1, 2020 | $10M Series A | — | Formic Ventures, Qiming Venture Partners, Bill Gates, Scott Becker | Announced |
| Aug 1, 2018 | $17M Series A | Qiming Venture Partners | Formic Ventures, Bill Gates, Scott Becker, Ascendin Investment, CTS Capital | Announced |
Cure Genetics is a clinical-stage biotechnology company developing first-in-class cell and gene therapies for solid tumors and genetic diseases using its proprietary AIMS CAR-NKT platform for enhanced tumor targeting and VELP™ AAV platform for precise gene delivery.[1][2][3][4] It serves patients with unmet needs in oncology (e.g., renal cell carcinoma) and genetic disorders affecting organs like the nervous system, heart, and kidneys, while partnering with pharma companies for licensing and co-development.[1][2][3] The company has raised over $7M in funding, achieved first-in-human CAR-NKT trials showing safety and anti-tumor activity, and secured global collaborations like with Boehringer Ingelheim.[1][3]
Founded in 2016 in Suzhou, China, Cure Genetics emerged from the vision of experts in cell therapy and gene editing to tackle limitations in treating solid tumors and genetic diseases.[2] Key founders include leaders with deep biotech pedigrees: one co-founder with government talent recognitions (e.g., Jiangsu Province Innovation Talent) and a professorship at Suzhou University, experienced in CAR-T and gene editing; Shawn, PhD from University of Maryland, who advanced three cell therapies to clinic at Celgene; and Dr. Zhao, expert in protein engineering and AAV discovery, with publications in top journals and collaborations like Boehringer Ingelheim.[2] Early traction came from building dual platforms, applying for over 30 patents, and government-backed projects, evolving into a pipeline with IND-enabling studies and global out-licensing.[1][2][3]
Cure Genetics rides the explosive growth in cell and gene therapy, a market projected to exceed $50B by 2030, fueled by advances in CAR therapies and AAV vectors amid rising cancer prevalence and rare disease diagnoses.[1][2] Timing is ideal post-2020s regulatory wins (e.g., FDA approvals for CAR-T), yet gaps in solid tumor efficacy and organ-specific delivery create tailwinds—its platforms solve these by improving infiltration and safety.[1][3] It influences the ecosystem through benchmarks like first CAR-NKT RCC trial, pharma partnerships accelerating INDs, and contributions to conferences (ASGCT, Frontiers in Immunology), fostering innovation in China's biotech hub and global licensing.[2][3]
Cure Genetics is poised for milestone-rich growth, with upcoming ASGCT data readouts, expanded VELP™ collaborations, and potential Phase II trials for CAR-NKT assets amid surging demand for next-gen therapies.[3] Trends like AI-accelerated vector design and combo immunotherapies will amplify its platforms, while China-U.S. biotech bridges enhance funding and trials. Its influence could evolve from innovator to category leader, delivering cures where others falter—watch for IND approvals and big-pharma buyouts to redefine oncology and gene therapy standards.[1][2][3]